Ian Piovanetti, MD
Ophthalmology · San Juan, PRNPI 1205897154
Payments from drug & device makers
Across 1,710 payments — averaging $424.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon Research LLC$716K
- Bausch & Lomb Americas Inc.$8K
- Alcon Puerto Rico Inc$874
- AbbVie$496
- Novartis$305
- NEW World Medical,inc.$188
- plus $584 from 5 others
What the payments were for
- Speaking & faculty fees$7,50071%
- Food & beverage$3,05529%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon Research LLC | 1,661 | $715,532 |
| Bausch & Lomb Americas Inc. | 11 | $8,120 |
| Alcon Puerto Rico Inc | 11 | $874 |
| AbbVie(2 entities) | 13 | $496 |
| Novartis | 4 | $305 |
| NEW World Medical,inc. | 2 | $188 |
| Alcon | 2 | $169 |
| Oculus, Inc. | 1 | $140 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $128 |
| Mallinckrodt Hospital Products Inc. | 1 | $125 |
| Dompe US, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RETISERT$7,500
- VISUDYNE$7,500
- STELLARIS$7,500
- Clareon$358
- MIEBO$250
- enVista MX60 IOL$250
- XIIDRA$226
- OCULUS Pentacam$140
- ACTHAR$125
- enVista Aspire IOL$125
- OZURDEX$125
- NGENUITY$110
- Clareon PanOptix Pro$107
- DURYSTA$102
- VYZULTA$100
How this compares
$726,099 in reported general payments places this provider in the 95th percentile of 214 ophthalmology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 472 | $127,933 |
| RestasisCyclosporine | 142 | $82,101 |
| Prednisolone Acetate | 849 | $36,043 |
| Ketorolac Tromethamine | 651 | $18,583 |
| Ofloxacin | 773 | $18,248 |
| Fluorometholone | 272 | $16,975 |
| Cyclosporine | 95 | $16,207 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 106 | $14,632 |
| Alphagan PBrimonidine Tartrate | 70 | $14,145 |
| CombiganBrimonidine Tartrate/Timolol | 60 | $13,236 |
| XiidraLifitegrast | 13 | $9,175 |
| Latanoprost | 617 | $8,873 |
| Brimonidine Tartrate | 51 | $7,480 |
| Lotemax SmLoteprednol Etabonate | 15 | $3,873 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 18 | $3,794 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Alphagan P, Combigan | $496 | $237,415744 claims |
| Bausch & Lomb Americas Inc.Xiidra | $8,120 | $9,17513 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm | $128 | $3,87315 claims |
| AlconSimbrinza | $169 | $3,79418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 214 ophthalmology providers in Puerto Rico.
Other ophthalmology in San Juan
- Jose MontesSan Juan$1.8M
- Maria Berrocal FernandezSan Juan$547K
- Juan Nevarez MarreroSan Juan$19K
- Natalio Izquierdo EncarnacionSan Juan$16K
- Jaime Bravo CastroSan Juan$8K
- Ernesto CollazoSan Juan$7K
- Gustavo HernandezSan Juan$5K
- Victor VillegasSan Juan$5K
- Gabriela Trabal YulfoSan Juan$4K
- Esteban Vazquez-ValenciaSan Juan$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.